Key result
HFrEF patients show poor guideline adherence, particularly the ~31% prescription rate for aldosterone antagonists.
Why the study?
What is the rate of adherence to current therapeutic guidelines among patients with chronic heart failure in an ambulatory cardiology setting?
Observational (n=660)
Yes
What is the rate of adherence to current therapeutic guidelines among patients with chronic heart failure in an ambulatory cardiology setting?
This registry highlights significant gaps in the implementation of guideline-directed medical therapy for heart failure, particularly the underutilization of aldosterone antagonists and implantable cardiac devices.
May worsen HFrEF outcomes; hypothesis-generating for implementation strategies targeting aldosterone antagonists and devices.
BACKGROUND: The prognosis of chronic heart failure (CHF) may be substantially improved by strict adherence to current therapeutic guidelines. AIM AND METHODS: To assess the adherence to current guidelines, 660 CHF patients consecutively referred to the ARCA (Associazioni Regionali Cardiologi Ambulatoriali Campania) cardiologists were evaluated. As indicators of adherence to the guidelines, we considered use of angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers, beta-blockers, loop diuretics, aldosterone antagonists, digoxin, anticoagulant therapy, and implantation of cardiac devices. RESULTS: The adherence to guidelines has been characterized in patients with reduced ejection fraction, who represent the majority in the ALERT-HF (Adherence to Guidelines in the Treatment of patients with Chronic Heart Failure) trial and in whom the current guidelines are well defined and shared. Among 528 patients affected by CHF with ejection fraction 45% or less, 399 (75.6%) were treated with a beta-blocker, 282 (53.4%) received an angiotensin-converting enzyme inhibitor and 199 (37.7%) an angiotensin receptor blocker. Four hundred and sixty-nine patients (88.9%) used loop diuretics, but only 163 patients (30.9%) an aldosterone antagonist. Among 148 patients with atrial fibrillation, 95 (64.2%) were treated with anticoagulants. As few as 31 patients received cardiac electrical stimulation devices: 10 patients were implanted with a cardioverter-defibrillator and 21 received a device for cardiac resynchronization therapy. CONCLUSION: The study reveals poor adherence to current therapeutic guidelines for CHF, particularly with regard to aldosterone antagonists and anticoagulant therapy in the presence of atrial fibrillation. Even poorer is the adherence to guidelines as regards the use of implantable cardiac devices. The underlying reasons are discussed in relation to the data of other registries.
No takes yet. Share an insight, caveat, or question.
Guarnaccia et al. (2014) conducted an observational in Chronic heart failure (n=660). Adherence to therapeutic guidelines was evaluated on Adherence to current therapeutic guidelines. Adherence to therapeutic guidelines in 528 patients with HFrEF was poor, particularly for aldosterone antagonists (30.9%), anticoagulants in atrial fibrillation (64.2%), and implantable devices.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: